$XTALPI(02228.HK) On the plane, reading some materials on Moderna, I suddenly feel that maybe Crownpeak's decision to abandon its own pipeline and focus solely on being a platform could be a mistake. This might be a potential concern and point of reflection for the market in its pricing. After all, the business model of a platform approach always lacks certainty. However, interestingly, Crownpeak's role in driving pipeline progress within the ecosystem is positive.

It really puts me in a dilemma.